

CHRISTIAN MEDICAL COLLEGE

DEPARTMENT OF CLINICAL BIOCHEMISTRY

CMC EXTERNAL QUALITY ASSURANCE SCHEME MONTHLY SUMMARY REPORT - JUNE 2023



Lab Name MEDITRUST DIAGNOSTIC CENTRE

Lab No 18608

Constituent Group

Chemistry II

Date of Result Entered :

20/06/2023

PT item

Lyophilized human serum based

Date of Report Published : 04/07/2023

SI.No	Analyte	Method / Principle Analyzer Name	No of	DV	Participants		Your	SDI	U	
31.110	Analyte	Name	Analyzer Name	Participants		CA		Value	SDI	U
1	GLUCOSE II	GOD-POD II	Any Analyser (Automation / Semi Automation)	1526	266.99	9.70	25.91	202.98 mg/dL	-2.47	1.33
2	UREA II	Urease UV / GLDH II	Any Analyser (Automation / Semi Automation)	1025	47.23	11.49	5.42	54.03 mg/dL	1.25	0.34
3	CREATININE II	Jaffes Kinetic- Alkaline Picrate II	Any Analyser (Automation / Semi Automation)	1158	1.04	15.24	0.16	1.34 mg/dL	1.90	0.01
4	T.BILIRUBIN II	Diazonium Salt (Colorimetric) / Jendrassik II	Any Analyser (Automation / Semi Automation)	1337	4.71	15.27	0.72	2.28 mg/dL	-3.38	0.04
5	T-PROTEIN II	Biuret - Colorimetric II	Any Analyser (Automation / Semi Automation)	1248	5.94	9.76	0.58	7.31 g/dL	2.36	0.03
6	ALBUMIN II	BCG - Colorimetric II	Any Analyser (Automation / Semi Automation)	1229	3.50	9.29	0.32	3.51 g/dL	0.03	0.02
7	URIC ACID II	Enzymatic / Uricase Colorimetric II	Any Analyser (Automation / Semi Automation)	1129	4.67	17.89	0.84	4.76 mg/dL	0.11	0.05
8	CHOLESTROL II	CHOD-PAP II	Any Analyser (Automation / Semi Automation)	1590	128.46	11.58	14.88	143.89 mg/dL	1.04	0.75
9	TRIGLYCERIDE II	GPO-PAP / Enzymatic Colorimetric / End Point II	Any Analyser (Automation / Semi Automation)	1346	160.03	14.05	22,49	187.37 mg/dL	1,22	1.23

SDI Range	Interpretation		
Within -1.00 to +1.00	Excellent.		
Within ±1.01 to ±2.00	Good.		
Within ±2.01 to ±2.99	Accept with caution. Warning Signal.		
Beyond ±3.0	Unacceptable performance. Action Signal.		

LAB ADDRESS:

MEDITRUST DIAGNOSTIC CENTRE 439, ANUKUL CHANDRA ROAD GARIA WEST BENGAL700084

> Coordinator Contact Details: Email:clinqc@cmcvellore.ac.in Contact Number: 0416-2283102

Panela Christudoss
Dr. Pamela Christudoss
CMC EQAS Coordinator

CMC EQAS Coordinator
Christian Medical College, Vellore

Homogeneity and Stability of the sample is passed.

Data in CMC EQAS reports is confidential

CMC EQAS does not sub contract any components

******** End of Report *******



Health is the first step to prosperity.

INV. No. Patient Name Age/Gen Referred By

Source

MTR-INV-G-248/2023(15079) Ms. MEHERUN KHATUN 27 Years | Female

Dr. A. ISLAM south60 OSS*

Barcode No Invoice Generated Sample Received

45775 06/07/2023 03:14 PM 06/07/2023 03:14 PM 06/07/2023 07:13 PM



Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range
UREA Serum Urea Method (Urease-GLDH)	24	mg/dL	15 - 40
CREATININE Serum Creatinine Method (Enzymatic Method)	0.82	mg/dL	0.6 - 1.1

ADVICE : CKD RISK MAP

KDIGO guideline, 2012 recommends Chronic Kidney disease (CKD) should be classified based on cause, GFR category and albuminuria (ACR) category.


GFR & ACR category combined together reflect risk of progression and helps clinician to identify individuals who are progressing at more rapid rate than anticipated

BILIRUBIN (TOTAL AND DIRECT)			
Serum Bilirubin (Total) Method (Jendrassik & Grof Method)	0.89	mg/dL	Upto 1.0
Serum Bilirubin (Conj) Method (Jendrassik & Grof Method)	0.21	mg/dL	Upto 0.25
Serum Bilirubin (Uncon) Method (Calculated)	0.68	mg/dL	<0.75

 \square 1. In newborns with CB levels \ge 0.5 mg/dL and <2 mg/dL, the infection must be ruled out, and the newborn should be observed. In newborns with levels ≥2 mg/dL, a more in-depth assessment of the hepatobiliary system is indicated. (interpreting conjugated bilirubin level in newborns, [Epub 2010 Nov 12])

~~~~~ End of report ~~~~~









EARE SARANI, KOLKATA 700071 (\*\*) 033 2282 7745 | 7118 | 7023

98316 06907 | 06905 | 06904 | 06903 | 06187 | 80020

info@wdcpl.com @ www.wdcpl.com

Patient ID: 8079

Patient Name: MS. MEHERUN KHATUN

Age / Sex: 27 years / Female

Referred By: SELF

**Bill No:** 15108

Registered On: Jul 07, 2023, 10:34 a.m.

Collected On: Jul 07, 2023, 10:36 a.m.

Reported On: Jul 07, 2023, 02:04 p.m.

**Test Description** Value(s) Units Reference Range

**Biochemistry** 

| Serum Bilirubin Total      | 0.91 | mg/dL | 0.30 - 1.00 |  |
|----------------------------|------|-------|-------------|--|
| Method : Malloy And Evelyn |      |       |             |  |
| Conjugated Bilirubin       | 0.22 | mg/dL | 0.10 - 0.30 |  |
| Unconjugated Bilirubin     | 0.69 | mg/dL | 0.20 - 0.70 |  |

Method : Calculated

\*\*END OF REPORT\*\*

Clinical correlation suggested

Checked By: Rabindra Nath Mahata

Dr. Kamalesh Chatterjee Ph.D F.A.I.C.(U.K)

Registered By: Arun Kumar Saha

**Consultant Biochemist** 



Reported By: Rabindra Nath Mahata





## (Department of Pathology)

Root cause analysis of outlier parameter for EQAS performance
Format No: MDC/FM/92
Check Points
Observations

| SL No   | Check Points                                                                                                                                   | Observations |  |  |  |  |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--|--|--|--|
|         |                                                                                                                                                |              |  |  |  |  |
| Name of | Parameter (s): T. Bilinubin (SDI = (-3.38))                                                                                                    | JONE JUNE    |  |  |  |  |
|         |                                                                                                                                                | 'ear: 2023   |  |  |  |  |
| CLERIC  | CALERRORS Date of testing -20/06/202                                                                                                           | 3            |  |  |  |  |
| 1.      | Transcription error (may be pre- or post-analytical factors)                                                                                   | - NJL-       |  |  |  |  |
| 2.      | Wrong method has been registered for analysis or method change not updated                                                                     | -NIL-        |  |  |  |  |
| МЕТНО   | DOLOGICAL PROBLEM                                                                                                                              |              |  |  |  |  |
| 3.      | Instrument function checks (e.g., temperatures, blank readings, pressures) not performed as necessary, or results not within acceptable range. |              |  |  |  |  |
| 4.      | Scheduled instrument maintenance not performed appropriately.                                                                                  | - NA -       |  |  |  |  |
| 5.      | Incorrect instrument calibration.                                                                                                              | -, NA-       |  |  |  |  |
| 6.      | Standards or reagents improperly reconstituted and stored, or inadvertently used beyond expiration date.                                       | - NA -       |  |  |  |  |
| 7.      | Instrument probes misaligned.                                                                                                                  | - NIL-       |  |  |  |  |
| 8.      | Problem with instrument data processing functions. The laboratory may need to contact the manufacturer to evaluate such problems.              |              |  |  |  |  |
| 9.      | Problem in manufacture of reagents / standards, or with instrument settings specified by manufacturer                                          | - NIL-       |  |  |  |  |
| 10.     | Carry-over from previous specimen.                                                                                                             | - NIL -      |  |  |  |  |
| 11.     | Automatic pipettor not calibrated to acceptable precision and accuracy.                                                                        | - NA -       |  |  |  |  |
| 12.     | Imprecision from result being close to detection limit of method.                                                                              | - NIL -      |  |  |  |  |
| 13.     | QC material not run within expiration date, or improperly stored                                                                               | - NIL-       |  |  |  |  |
| 14.     | QC material not run at relevant analyte concentration - NJL -                                                                                  |              |  |  |  |  |
| 15.     | Result not within reportable range (linearity) for instrument / reagent system.                                                                | - NIL-       |  |  |  |  |



## (Department of Pathology)

Root cause analysis of outlier parameter for EQAS performance

Format No: MDC/FM/92

|       |                                                                                                                                                                                                              | mat No. MDC/FM/92                                                       |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| SL No | Check Points                                                                                                                                                                                                 | Observations                                                            |
| 16.   | Obstruction of instrument tubing / orifice by clot or protein.                                                                                                                                               |                                                                         |
|       |                                                                                                                                                                                                              | - NIL-                                                                  |
| 17.   | Incorrect incubation times.                                                                                                                                                                                  | - NIL-                                                                  |
| TECHN | ICAL PROBLEM                                                                                                                                                                                                 |                                                                         |
| 18.   | EQA material improperly reconstituted.                                                                                                                                                                       | - NIL-                                                                  |
| 19.   | Testing delayed after reconstitution of EQA material (with problem from evaporation or deterioration).                                                                                                       | -NIL-                                                                   |
| 20.   | Sample not placed in proper order on instrument.                                                                                                                                                             | ーハゴトー                                                                   |
| 21.   | Result released despite unacceptable QC data.                                                                                                                                                                | - NIL-                                                                  |
| 22.   | QC data within acceptable limits but showed trend suggestive of problem with the assay.                                                                                                                      | It shows thend but sample was tested with out taking corrective action, |
| 23.   | Inappropriate quality control limits / rules. If the acceptable QC range is too wide, the probability increases that a result will fall within the acceptable QC range yet exceed acceptable limits for EQA. |                                                                         |
| 24.   | Manual pipetting / diluting performed inaccurately, at an incorrect temperature or with incorrect diluent.                                                                                                   | - NIL-                                                                  |
| 25.   | Calculation error or result reported using too few significant digits.                                                                                                                                       | -NIL-                                                                   |
| 26.   | Secondary specimen tubes incorrectly labeled.                                                                                                                                                                | - NIL-                                                                  |
| PROBL | EM WITH PROFICIENCY TESTING MATERIALS                                                                                                                                                                        |                                                                         |
| 27.   | PT sample with appropriate matrix to that as prescribed by the equipment manufacturer for testing of samples.                                                                                                | - NIL -                                                                 |
| 28.   | Non-homogenous test material                                                                                                                                                                                 | - NIL-                                                                  |
| 29.   | Haemolysis on an immune-haemtology program samples.                                                                                                                                                          | -NIL-                                                                   |
| PROBL | EM WITH EVALUATION OF RESULTS BY THE PT PROVI                                                                                                                                                                | DER                                                                     |
| 30.   | Peer group not appropriate.                                                                                                                                                                                  | - NA -                                                                  |
| 31.   | Inappropriate target value                                                                                                                                                                                   | - NA                                                                    |
|       |                                                                                                                                                                                                              |                                                                         |



(Department of Pathology)

Root cause analysis of outlier parameter for EQAS performance

Format No: MDC/FM/92

| _ No | Check Points                        | Observations |
|------|-------------------------------------|--------------|
| 32.  | Incorrect data entry by PT provider | - NA -       |



(Department of Pathology)

Root cause analysis of outlier parameter for EQAS performance

| CI No | CLIDI        | Format No: MDC/FM/92 |
|-------|--------------|----------------------|
| SL No | Check Points | Observations         |
|       |              |                      |

### CONCLUSION:

Red done, however no major cause of Outlayer was identified. cause of such errors may be random. The parameter Total Bilionubin shall be send for ILC to NABL accredited lab. The parameter shall be strictly monitor in the next earlast eyele.

Root Cause Analysis done by: close monitoring of control values T. Bill
Remarks: for trend identification to be done.

Reviewed By: Suy



#### MEDITRUST DIAGNOSTIC CENTRE (Department of Pathology) EQAS Corrective Action Details

Format No: MDC/FM/93 Remarks & Corrective Action Taken **EQAS** Agency Sample Cycle No/ Parameter Reviewed By No **Testing Date** Sample No Outlier ILC has been done, After connective action Z-Score found 0.70 and cmc 20/06/2023 June, T. Bilinubin 1. Vellone 2023 the parameter will be monitored in next eyele. Rea done and it has been observed 20/06/2023 June cme 2. Glucose os Randon ervion. Parameter will be monitored in next cycle. After 2023 vellore (warning corrective oction Z-score found 0.70 South hos seen norm. RCA done and it has been observed eme 20/06/2023 June, as forder error, farameter will be monitored in next crete. After corrects action Z-scene Jound 070 sample has been neverun. T-Protein 3. vellone 2023

# MEDITRUST DIAGNOSTIC CENTRE (Department of Pathology)

Laboratory 1 : WESTERN

Laboratory 2 :

Laboratory` 3 :

| SI. No | Date of<br>Testing | ID No | Parameter   | MDC  | Lab 1 | Lab 2 | Lab 3 | Mean | SD       | Z-Score  |
|--------|--------------------|-------|-------------|------|-------|-------|-------|------|----------|----------|
| 1      | 07.07.2023         |       | T.BILIRUBIN | 0.89 | 0.91  |       |       | 0.9  | 0.014142 | -0.70711 |

Z- Score = (Lab 1 - Mean)/SD

| Corrective       |             |
|------------------|-------------|
| action<br>(≥2 Z- | Reviewed By |
| score)           |             |
| NA               | Ang.        |